13
Views
32
CrossRef citations to date
0
Altmetric
Original Article

Effect of hyperthermia on intracellular drug accumulation and chemosensitivity in drug-sensitive and drug-resistant P388 leukaemia cell lines

, , &
Pages 163-172 | Received 12 Oct 1987, Accepted 25 May 1988, Published online: 09 Jul 2009

References

  • Barlogie B., Corry P. M., Yip E., Lippman L., Johnston D. A., Khalil K., Tencrysnki T. F., Reilly E., Lawson R., Dosik G., Rigor B., Hankenson R., Freireich E. J. Total body hyperthermia with and without chemotherapy for advanced human neoplasms. Cancer Research 1979; 39: 1481–1489
  • Barlogie B., Corry P. M., Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichloro-diammine platinum (II) and mitomycin C. Cancer Research 1980; 40: 1165–1168
  • Capranico G., Dasdia T., Zunino F. Comparison of doxorubicin induced DNA damage in doxorubicin-sensitive and -resistant P388 murine leukemia cells. International Journal of Cancer 1986a; 37: 227–231
  • Capranico G., Soranzo C., Zunino F. single-strand breaks induced by chromophore-modified anthracyclines in P388 leukemia cells. Cancer Research 1986b; 46: 5499–5503
  • Curt G. A., Clendininn N. J., Chabner B. A. Drug resistance in cancer. Cancer Treatment Reports 1984; 68: 87–99
  • Fisher G., Hahn G. M. Enhancement of cis-platinum (II) diamminechloride cytotoxicity by hyperthermia. National Cancer Institute Monographs 1982; 61: 255–257
  • Garman D., Center M. S. Alterations in cell surface membranes in Chinese hamster lung cells resistant to adriamycin. Biochemical and Biophysical Research Communications 1982; 105: 157–163
  • Goldenberg G. J., Wand H., Blair G. W. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia. Cancer Research 1986; 46: 2978–2983
  • Greco C., Cavaliere R., Natali P. G., Zuppi G. Effect of hyperthermia combined with antineoplastic drugs. Proceedings of the American Association for Cancer Research. 1983. 24: 265
  • Hahn G. M., Braun J., Har-Kedar I. Thermochemotherapy: synergism between hyperthermia (42°-43°C) and adriamycin (or bleomycin) in mammalian cell inactivation. Proceedings of the National Academy of Sciences, U.S.A. 1975; 72: 937–940
  • Herman T. S. Temperature dependence of adriamycin, cw-diammine-dichloroplatinum, bleomycin and 1,3 bis (2-chloroethyl) 1-nitrosurea cytotoxicity in vitro. Cancer Research 1983; 43: 517–520
  • Inaba M., Kobayashi H., Sakurai Y., Johnson R. K. Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Research 1979; 39: 2200–2203
  • Kaye S., Merry S. Tumour cell resistance to anthracyclines-a review. Cancer Chemotherapeutics and Pharmacology 1985; 14: 96–103
  • Kessel D., Wilberding C. Anthracycline resistance in P388 murine leukemia and its circumvention by calcium antagonists. Cancer Research 1985; 45: 1687–1691
  • Lepok J. Involvement of membranes in cellular responses to hyperthrmia. Radiation Research 1982; 92: 433–438
  • Li G., Han G. Adaptation to different growth temperatures modifiies some mammalian cell survivor responses. Experimental Cell Research 1980; 128: 475–480
  • Marmor J., Kozak D., Hahn G. Effect of systemically administered bleomycin or adriamycin with local hyperthermia on primary tumor and lung metastases. Cancer Treatment Reports 1979; 63: 1279–1290
  • Peterson R. M. F., Meyers M. B., Spengler B. A., Biedler J. Alteration of plasma membrane glycopeptides and gangliosides of Chinese hamster cell accompanying development of resistance to daunomycin and vincristine. Cancer Research 1983; 43: 228–228
  • Pommier Y., Kerrigan D., Schwartz R. E., Swack J. A., McCurdy A. Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Research 1986; 46: 3057–3081
  • Wallner K. E., De Gregorio M. W., Li G. C. Hyperthermic potentiation of cis-diamminedichloroplatinum (II) cytotoxicity in Chinese hamster ovary cells resistant to the drug. Cancer Research 1986; 46: 6242–6245

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.